We observed that the overexpression of HRAS in the tumor tissues compared to matched healthy tissues significantly correlated with responsiveness of primary NET cells to lenvatinib (p=.048) (Table 2 and Figure 4A). This evidence concerns the gene HRAS and neoplasm.